KNSA

KNSA

USD

Kiniksa Pharmaceuticals International plc Class A Ordinary Shares

$38.755-0.325 (-0.832%)

Echtzeitkurs

Healthcare
Drug Manufacturers - Specialty & Generic
Vereinigtes Königreich

Kursdiagramm

Loading Chart...

Schlüsselkennzahlen

Marktkennzahlen
Unternehmensfundamentaldaten
Handelsstatistiken

Marktkennzahlen

Eröffnung

$39.080

Hoch

$39.220

Tief

$38.570

Volumen

0.35M

Unternehmensfundamentaldaten

Marktkapitalisierung

2.9B

Branche

Drug Manufacturers - Specialty & Generic

Land

United Kingdom

Handelsstatistiken

Durchschnittliches Volumen

0.46M

Börse

NMS

Währung

USD

52-Wochen-Spanne

Tief $17.82Aktuell $38.755Hoch $42.05

Ähnliche Nachrichten

Analyst Upgrades

Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $55

Goldman Sachs analyst Paul Choi maintains Kiniksa Pharmaceuticals with a Buy and raises the price target from $45 to $55.

Mehr anzeigen
Goldman Sachs Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $55
GlobeNewswire

Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution

– ARCALYST® (rilonacept) Q3 2025 net product revenue of $180.9 million, representing 61% year-over-year growth –– ARCALYST 2025 expected net product revenue raised to $670 - $675 million –– KPL-387 granted Orphan

Mehr anzeigen
Kiniksa Pharmaceuticals Reports Third Quarter 2025 Financial Results and Recent Portfolio Execution
Analyst Upgrades

Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $44

Wedbush analyst David Nierengarten maintains Kiniksa Pharmaceuticals with a Outperform and raises the price target from $38 to $44.

Mehr anzeigen
Wedbush Maintains Outperform on Kiniksa Pharmaceuticals, Raises Price Target to $44

Bleiben Sie auf dem Laufenden

Preisalarme setzen, KI-Analyse-Updates und Echtzeit-Marktnachrichten erhalten.